Tema Oncology ETF (NASDAQ:CANC) Sees Significant Decline in Short Interest

Tema Oncology ETF (NASDAQ:CANC) was the target of a large decline in short interest in October. As of October 30th, there was short interest totaling 3,276 shares, a decline of 69.1% from the October 15th total of 10,591 shares. Approximately 0.1% of the shares of the stock are sold short. Based on an average daily volume of 14,533 shares, the days-to-cover ratio is presently 0.2 days.

Tema Oncology ETF Stock Performance

Shares of CANC traded down $0.07 during midday trading on Friday, hitting $41.14. 13,124 shares of the company traded hands, compared to its average volume of 30,022. The stock has a market cap of $210.23 million, a price-to-earnings ratio of 20.39 and a beta of 0.70. The firm has a 50 day moving average of $41.63 and a 200-day moving average of $39.51. Tema Oncology ETF has a 52 week low of $32.88 and a 52 week high of $47.00.

Hedge Funds Weigh In On Tema Oncology ETF

An institutional investor recently raised its stake in Tema Oncology ETF stock. Roxbury Financial LLC grew its position in Tema Oncology ETF (NASDAQ:CANC) by 9.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,325 shares of the company’s stock after acquiring an additional 385 shares during the quarter. Roxbury Financial LLC owned 0.09% of Tema Oncology ETF worth $182,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Tema Oncology ETF Company Profile

The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.